Better AML outcomes are possible when rapid, detailed genetic insights guide decisions.

We don’t expect you to put your patients’ critical diagnostic testing in the hands of just anyone. For over 20 years, we set the standard for quality, accurate, and reliable solutions to deliver precise answers that you know you can trust. NEO | AML Express delivers class-leading turnaround times and a guideline-driven, NGS-based assessment with actionable diagnostic, prognostic, and predictive information in 3-5 days. This allows you to make the right decision at the right time for your patient.

Rapid TAT of crucial biomarker insights drives personalized treatment decisions, ensuring that your patients receive the most current and effective treatments, improving outcomes and enhancing their quality of life.

The NEO | AML Express assay is a next-generation sequencing (NGS) assay using combined DNA- and RNA-sequencing, which is used to identify prognostically and diagnostically informative alterations in acute myeloid leukemia (AML). The DNA sequencing component of this assay detects single nucleotide variants (SNVs) and indels in genes recurrently mutated in AML, and the RNA sequencing component detects fusions involving genes that are frequently involved in structural rearrangements observed in AML, as noted below. Test reports include a summary interpretation of all results together.